SOLVE FSHD Accelerates Development of SFH-4090, a Novel DUX4 Inhibitor for FSHD

SOLVE FSHD announces new nonclinical data supporting SFH-4090 development for FSHD, a progressive muscle-wasting disease with no approved disease-modifying therapies The data, presented at the World Muscle Society Annual Congress 2026, build on SFH-4090’s novel chemistry for ASO therapies, with improved tissue penetration following subcutaneous delivery Findings show SFH-4090 reaches and remains in skeletal muscle, […]